TechLab Receives FDA Clearance To Market Tri-Combo Parasite Screen

23:53 EDT 20 Jul 2017 | Virginia Biotechnology

TECHLAB, Inc., a leading developer and manufacturer of rapid non-invasive diagnostic tests for gastrointestinal diseases, has received U.S. Food and Drug Administration (FDA) clearance for the TRI-COMBO PARASITE SCREEN™ test. The TRI-COMBO PARASITE SCREEN ™ test provides a complete analysis for Giardia, Cryptosporidium, and Entamoeba histolytica, the three most common intestinal protozoan parasites. It specifically detects pathogenic E. histolytica and does not cross react with non-pathogenic E. dispar.

Giardia, Cryptosporidium, and E. histolytica are the most common parasitic causes of diarrhea in the United States. The TRI-COMBO PARASITE SCREEN™ test is an enzyme immunoassay for the simultaneous qualitative detection of Giardia spp., Cryptosporidium spp., and/or E. histolytica antigen in human fecal specimens. It is indicated as an aid in the diagnosis of gastrointestinal infection when giardiasis, cryptosporidiosis and amebiasis is suspected.

"This new and unique assay will make testing for the three most common causes of parasitic gastroenteritis more efficient and cost-effective," said David Lyerly, Ph.D., Chief Scientific Officer, TECHLAB®.

Original Article: TechLab Receives FDA Clearance To Market Tri-Combo Parasite Screen


More From BioPortfolio on "TechLab Receives FDA Clearance To Market Tri-Combo Parasite Screen"

Quick Search


Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Enzymes are proteins that catalyze (i.e., increase the rates of) chemical reactions. In enzymatic reactions, the molecules at the beginning of the process, called substrates, are converted into different molecules, called products. Almost all chemical re...